Personalized Drug Screening in Patient-Derived Gastroenteropancreatic Neuroendocrine Tumors
Overview
A standardized platform for personalized drug screening was developed using patient-derived gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN) primary cultures. This approach identified significant differences in drug responses between tumor subtypes and enabled individualized prediction of treatment efficacy.
Background
Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) include well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs), with survival outcomes varying by tumor type, grade, and metastatic status. Current systemic therapies, including somatostatin analogues and targeted agents like mTOR inhibitors and tyrosine kinase inhibitors, are applied largely without personalization. There is an unmet need for precision medicine approaches to improve treatment outcomes in metastatic GEP-NENs.
Data Highlights
Parameter
Value
Number of primary cultures established
23 (16 metastatic)
Tumor types
12 small intestinal NETs, 10 pancreatic NETs, 1 NEC
Established a reproducible protocol for generating patient-derived GEP-NEN primary cultures for drug screening.
Demonstrated statistically significant group effects and individual variability in drug responsiveness and resistance.
Identified differential drug responses between pancreatic NETs and small intestinal NETs.
Observed distinct drug sensitivity profiles between GEP-NETs and GEP-NECs.
Provided novel efficacy data for both established therapies (e.g., everolimus, sunitinib) and investigational agents (e.g., niraparib, adavosertib) in GEP-NEN cultures.
Incorporated personalized risk assessment including evaluation of hormone analogues and sex hormones.
Clinical Implications
This personalized drug screening platform enables clinicians to predict individual tumor responses, potentially guiding tailored therapeutic strategies in GEP-NEN patients. The approach may improve treatment selection beyond current nonpersonalized systemic therapies, especially for metastatic disease with poor prognosis. Integration of such precision medicine tools could optimize outcomes and reduce exposure to ineffective treatments.
Conclusion
The study establishes a novel, standardized method for individualized drug evaluation in GEP-NENs, revealing subtype-specific drug sensitivities and supporting precision oncology approaches in this rare tumor group.
References
Clinical Research Article -- Customized Drug Evaluation and Risk Profiling in Patient-Derived Gastroenteropancreatic Neuroendocrine Tumors
by Christoph J Auernhammer, Katharina Wang, Umberto Maccio, Thomas Knösel, Maximilian P Hungbauer, Katharina Schilbach, Julian Maurer, Lea Peischer, Astrid Reul, Elena Kuzmenko, Edlira Luca, Julia Hamati, Diana Vetter, Jose Oberholzer, Ralph Fritsch, Karel Pacak, Ashley B Grossman, Felix Beuschlein, Martin Reincke, Constanze Hantel, Kathrin Zitzmann, Svenja Nölting
More than 80% of women who were partially up to date reported a wellness visit in the prior year, suggesting missed opportunities for screening engagement in primary care.
